IGF-1 and Bone Loss in Women With Anorexia Nervosa.

Trial Profile

IGF-1 and Bone Loss in Women With Anorexia Nervosa.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Aug 2018

At a glance

  • Drugs Mecasermin (Primary) ; Risedronic acid
  • Indications Osteoporosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Jul 2018 Status changed from recruiting to active, no longer recruiting.
    • 30 Jul 2018 Planned End Date changed from 1 Oct 2018 to 1 Mar 2019.
    • 30 Jul 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top